SG11201702056YA - Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition - Google Patents
Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibitionInfo
- Publication number
- SG11201702056YA SG11201702056YA SG11201702056YA SG11201702056YA SG11201702056YA SG 11201702056Y A SG11201702056Y A SG 11201702056YA SG 11201702056Y A SG11201702056Y A SG 11201702056YA SG 11201702056Y A SG11201702056Y A SG 11201702056YA SG 11201702056Y A SG11201702056Y A SG 11201702056YA
- Authority
- SG
- Singapore
- Prior art keywords
- mediating
- treatment
- hiv
- monoclonal antibodies
- competitive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051200P | 2014-09-16 | 2014-09-16 | |
| PCT/US2014/065048 WO2016043788A1 (en) | 2014-09-16 | 2014-11-11 | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201702056YA true SG11201702056YA (en) | 2017-04-27 |
Family
ID=55533661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702056YA SG11201702056YA (en) | 2014-09-16 | 2014-11-11 | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11180555B2 (en) |
| EP (1) | EP3194442A4 (en) |
| JP (2) | JP6716544B2 (en) |
| KR (1) | KR20170054478A (en) |
| CN (1) | CN107074944A (en) |
| AU (2) | AU2014406462A1 (en) |
| BR (1) | BR112017005134A2 (en) |
| CA (1) | CA2961464A1 (en) |
| MX (1) | MX2017003546A (en) |
| RU (1) | RU2762315C2 (en) |
| SG (1) | SG11201702056YA (en) |
| TW (1) | TWI695720B (en) |
| WO (1) | WO2016043788A1 (en) |
| ZA (1) | ZA201701856B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11292839B2 (en) * | 2016-08-13 | 2022-04-05 | Ubi Us Holdings, Llc | Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients |
| JP2021523929A (en) * | 2018-03-05 | 2021-09-09 | オンコイミューン， インコーポレイテッド | How to use soluble CD24 for the treatment of acquired immunodeficiency syndrome (HIV / AIDS) |
| WO2021146272A1 (en) * | 2020-01-13 | 2021-07-22 | The Regents Of The University Of California | Methods for treating viral infections |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4381295A (en) | 1979-04-26 | 1983-04-26 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human helper T cells and methods of preparing same |
| DE3828582A1 (en) | 1988-08-23 | 1990-03-01 | Max Planck Gesellschaft | MONOCLONAL ANTIBODY TO INHIBIT THE INFECTION OF CELLS BY HIV VIRUSES |
| EP0365209A3 (en) | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Anti-leu 3a amino acid sequence |
| JPH0725794B2 (en) | 1990-03-23 | 1995-03-22 | 呉羽化学工業株式会社 | Novel peptide |
| JPH05505112A (en) | 1990-11-27 | 1993-08-05 | バイオジェン，インコーポレイテッド | Anti-CD4 antibody homologues useful in the prevention and treatment of AIDS, ARC and HIV infections |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH06125783A (en) | 1991-12-28 | 1994-05-10 | Chemo Sero Therapeut Res Inst | Recombinant anti-hiv antibody and its preparation |
| DE69535002T2 (en) | 1994-03-08 | 2006-12-07 | Memorial Sloan-Kettering Cancer Center | RECOMBINANT HUMANIZED ANTIBODIES AGAINST FB5 |
| US5961976A (en) | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
| US5962319A (en) | 1997-05-19 | 1999-10-05 | Bml, Inc. | Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene |
| JP3231262B2 (en) | 1996-06-05 | 2001-11-19 | 株式会社ビー・エム・エル | Human Th1-specific protein, gene encoding the same, and transformants, recombinant vectors and antibodies related thereto |
| JPH10155489A (en) | 1996-11-27 | 1998-06-16 | Asahi Chem Ind Co Ltd | Recombinant antibody and nucleic acid coding for the same |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| WO1999061629A1 (en) | 1998-05-25 | 1999-12-02 | Asahi Kasei Kogyo Kabushiki Kaisha | Cell separation device and separation method |
| US6090388A (en) | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
| PE20001548A1 (en) | 1999-03-02 | 2001-01-16 | Schering Corp | USE OF PEGILATED ALPHA INTERFERON FOR THE TREATMENT OF HIV-1 |
| DK1454137T3 (en) | 2001-12-11 | 2008-06-16 | Biotectid Gmbh | Use of a labeled ligand with specificity for the human CD4 molecule |
| JP2003327536A (en) | 2002-03-07 | 2003-11-19 | Kitasato Inst:The | Infection and growth inhibitor of human immunodeficiency syndrome virus |
| US20030211470A1 (en) | 2002-03-15 | 2003-11-13 | Olson William C. | CD4-IgG2-based salvage therapy of HIV-1 infection |
| US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| KR100633856B1 (en) * | 2005-07-08 | 2006-10-13 | 조통래 | Diseases and pests control agent of crops dissolved micro-bubbles, containing oxygen and ozone |
| WO2007094983A2 (en) * | 2006-02-03 | 2007-08-23 | Tanox, Inc. | Methods and compositions for the inhibition of hiv infection of t cells |
| US20130195881A1 (en) * | 2007-04-27 | 2013-08-01 | Sanjaya Singh | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
-
2014
- 2014-11-11 CA CA2961464A patent/CA2961464A1/en active Pending
- 2014-11-11 WO PCT/US2014/065048 patent/WO2016043788A1/en active Application Filing
- 2014-11-11 JP JP2017514874A patent/JP6716544B2/en active Active
- 2014-11-11 RU RU2017112967A patent/RU2762315C2/en not_active Application Discontinuation
- 2014-11-11 BR BR112017005134A patent/BR112017005134A2/en not_active IP Right Cessation
- 2014-11-11 AU AU2014406462A patent/AU2014406462A1/en not_active Abandoned
- 2014-11-11 CN CN201480081992.3A patent/CN107074944A/en active Pending
- 2014-11-11 US US15/512,043 patent/US11180555B2/en active Active
- 2014-11-11 MX MX2017003546A patent/MX2017003546A/en unknown
- 2014-11-11 SG SG11201702056YA patent/SG11201702056YA/en unknown
- 2014-11-11 EP EP14902149.5A patent/EP3194442A4/en not_active Ceased
- 2014-11-11 KR KR1020177009857A patent/KR20170054478A/en not_active Application Discontinuation
-
2015
- 2015-09-16 TW TW104130548A patent/TWI695720B/en active
-
2017
- 2017-03-15 ZA ZA2017/01856A patent/ZA201701856B/en unknown
-
2019
- 2019-11-01 JP JP2019199493A patent/JP2020097569A/en active Pending
-
2021
- 2021-05-13 AU AU2021203071A patent/AU2021203071A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170369576A1 (en) | 2017-12-28 |
| CN107074944A (en) | 2017-08-18 |
| TWI695720B (en) | 2020-06-11 |
| JP2017529355A (en) | 2017-10-05 |
| EP3194442A1 (en) | 2017-07-26 |
| RU2017112967A (en) | 2018-10-17 |
| JP2020097569A (en) | 2020-06-25 |
| US11180555B2 (en) | 2021-11-23 |
| JP6716544B2 (en) | 2020-07-01 |
| CA2961464A1 (en) | 2016-03-24 |
| KR20170054478A (en) | 2017-05-17 |
| WO2016043788A1 (en) | 2016-03-24 |
| AU2021203071A1 (en) | 2021-06-17 |
| BR112017005134A2 (en) | 2017-12-12 |
| AU2014406462A1 (en) | 2017-04-06 |
| RU2762315C2 (en) | 2021-12-17 |
| TW201611845A (en) | 2016-04-01 |
| ZA201701856B (en) | 2020-08-26 |
| EP3194442A4 (en) | 2018-05-23 |
| RU2017112967A3 (en) | 2018-10-17 |
| MX2017003546A (en) | 2017-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102219B (en) | Dosage and administration of non-fucosylated anti-cd40 antibodies | |
| IL267798B (en) | Human antibodies to pd-1 | |
| ZA201706155B (en) | Neutralizing antibodies to gp120 and their use | |
| HK1245331A1 (en) | Combination of listeria-based vaccine with anti-ox40 or anti-gitr antibodies | |
| HK1225968A1 (en) | Combination therapy for treatment of hbv infections | |
| HK1223931A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
| IL258191A (en) | Method of redirecting t cells to treat hiv infection | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| IL252535A0 (en) | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) | |
| GB201618424D0 (en) | Treatment of antibody mediated disease | |
| DK3250600T3 (en) | TREATMENT OF AUTOIMMUNE DISEASES WITH CD154 ANTIBODIES | |
| ZA201701856B (en) | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition | |
| DK2991664T3 (en) | Means for the prevention and treatment of sequelae of HIV and other viral infections | |
| IL260094A (en) | Treatment of hand eczema | |
| GB201400005D0 (en) | Treatment of auto immune diseases useing monocloani antibodies | |
| TH1501005991A (en) | Macrocyclic diesa-purinone To treat viral infections | |
| TH1601001266A (en) | Methods and pharmaceutical compositions for the treatment of hepatitis B infection. |